TIDMFUM

RNS Number : 1058O

Futura Medical PLC

05 October 2021

Directors' / PDMR Dealing and Grant of Options

5 October 2021

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology currently focused on sexual health and pain, today announces that on 4 October 2021 it made its annual grant of options over a total of 1,654,800 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 858,000 options were granted to Directors and PDMRs as detailed below.

 
                                                        Total number 
                  Number                                  of options  Total number 
              of options  Exercise                    held following   of Ordinary 
Director         granted     price  Exercise period     notification   Shares held 
-----------  -----------  --------  ---------------  ---------------  ------------ 
 
                                    1 Oct 2023 - 30 
J H Barder       330,000     37.9p         Sep 2028        1,880,000     1,210,972 
 
                                    1 Oct 2023 - 30 
A Hildreth       264,000     37.9p        Sept 2028          904,000       142,857 
 
                                    1 Oct 2023 - 30 
K W James        264,000     37.9p        Sept 2028        1,304,000       299,581 
 

Of the total 1,654,800 options, 1,155,122 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 499,678 were granted under the unapproved scheme.

The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise. Further disclosures are contained in the tables below.

S

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: +44 (0) 203 100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) technology. Each DermaSys(R) formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             James Barder 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Chief Executive Officer 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          37.90 pence      330,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          4 October 2021 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Angela Hildreth 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Finance Director and 
                                        Chief Operating Officer 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          37.90 pence      264,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          4 October 2021 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Ken James 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Executive Director 
                                        and Head of R&D 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          37.90 pence      264,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          4 October 2021 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFIEIVLEIIL

(END) Dow Jones Newswires

October 05, 2021 11:05 ET (15:05 GMT)

Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Futura Medical
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Futura Medical